Adenoid cystic/basal cell carcinoma of the prostate: case report

Tonini, Gerolamo; Rosini, Roberto; Teppa, Alessandro; Aulenti, V.; Kalantary, Farschid; Tosana, M; Bianchi, Denise; Zorzi, Fausto

doi:10.1177/039156030807500409

Cited by 2 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…yielded 98 cases of PBCC upon searching the PubMed electronic database. A wider search of the literature by our group revealed a total of 139 cases, of which 102 cases were published clinical reviews . When summarizing these cases, the mean age at PBCC diagnosis was 67.9 ± 11.6, and the mean period of follow‐up was 37.7 ± 37.3 months.…”

Section: Discussionmentioning

confidence: 99%

“…A wider search of the literature by our group revealed a total of 139 cases, of which 102 cases were published clinical reviews. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] When summarizing these cases, the mean age at PBCC diagnosis was 67.9 AE 11.6, and the mean period of follow-up was 37.7 AE 37.3 months. The most common primary complaint for these men was urinary obstruction.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Primary basal cell carcinoma of the prostate with concurrent adenocarcinoma

et al. 2020

View full text Add to dashboard Cite

Introduction Prostatic basal cell carcinoma is an extremely rare tumor, exhibiting various histopathological features and clinical spectrums of disease. Case presentation A 69‐year‐old male presented to our department with 2 years of voiding difficulty and intermittent macroscopic hematuria. With a presumed diagnosis of benign prostatic hyperplasia, he underwent a transurethral resection of the prostate. Pathological examination revealed atypical basaloid cells forming solid nests. Robot‐assisted radical prostatectomy was subsequently performed, confirming a diagnosis of basal cell carcinoma with coexisting acinar adenocarcinoma. Conclusion Although more cases of basal cell carcinoma are indolent than aggressive, there is no reliable method of differentiation between these presentations. Thus, we recommend radical surgery and 6‐monthly disease surveillance until more is discovered about this very rare malignancy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Primary basal cell carcinoma of the prostate with concurrent adenocarcinoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Until recently, only 99 cases of primary BCC of the prostate had been reported (1). Typically, BCC of the prostate possesses low malignancy potential; however, there are reports of aggressive BBC leading to metastasis and recurrence (2)(3)(4)(5). Owing to the limited number of cases, proper management strategies are still lacking for prostate BCC.…”

Section: Introductionmentioning

confidence: 99%

An Unusual Case of Metastatic Basal Cell Carcinoma of the Prostate: A Case Report and Literature Review

Dong

Liu

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Background: Primary basal cell carcinoma (BCC) is a rare prostate cancer. Currently, a standard treatment regime for BCC of the prostate is lacking and most patients have a poor prognosis. We reported on a patient with BCC of the prostate whose cancer metastasized after undergoing a radical prostatectomy and whose prognosis improved after treatment with etoposide. Case Presentation: A 62-year-old male with a history of seminoma was admitted complaining of intermittent gross hematuria for 1 month. Following a prostate biopsy, the patient was diagnosed with BCC of the prostate and received radical prostatectomy and radiotherapy. Initially, the patient's symptoms improved; however, 2 years later, a chest computed tomography (CT) scan revealed lung nodules. The patient did not exhibit any symptoms of BCC of the prostate; however, pathological examination and immunohistochemical staining of the nodules confirmed metastatic BCC of the prostate. Chemotherapy with docetaxel and cisplatin was well-tolerated but did not slow disease progression. Next-generation sequencing revealed mutations in the ataxia telangiectasia-mutated (ATM), SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily b-member 1 (SMARCB1), and phosphoinositide-3kinase regulatory subunit 1 (PIK3R1) genes. The patient did not receive targeted therapy owing to financial limitations and instead, etoposide was administered. A 9-month followup chest CT scan showed an 80% reduction in existing lung nodules and no new nodules had developed. Conclusion: Our patient, diagnosed with recurrent prostate BCC after receiving a radical prostatectomy, responded to treatment with etoposide. Radical prostatectomy and radiotherapy should remain first-line therapy; however, etoposide may be an alternative second-line therapy when other options are not available. Consensus regarding treatment plans, and the molecular mechanisms behind prostate BBC, must be elucidated.

show abstract

Adenoid cystic/basal cell carcinoma of the prostate: case report

Cited by 2 publications

References 12 publications

Primary basal cell carcinoma of the prostate with concurrent adenocarcinoma

Primary basal cell carcinoma of the prostate with concurrent adenocarcinoma

An Unusual Case of Metastatic Basal Cell Carcinoma of the Prostate: A Case Report and Literature Review

Contact Info

Product

Resources

About